Location via proxy:   [ UP ]  
[Report a bug]   [Manage cookies]                
eISSN: 2449-8238
ISSN: 2392-1099
Clinical and Experimental Hepatology
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
3/2019
vol. 5
 
Share:
Send email
Share:
abstract:
Review paper

Prophylaxis of hepatitis B virus (HBV) infection reactivation – recommendations of the Working Group for prevention of HBV reactivation

Małgorzata Pawłowska
1
,
Robert Flisiak
2
,
Lidia Gil
3
,
Andrzej Horban
4
,
Iwona Hus
5, 6
,
Jerzy Jaroszewicz
7
,
Ewa Lech-Marańda
5
,
Jan Styczyński
8

  1. Department of Infectious Diseases and Hepatology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Poland
  2. Department of Infectious Diseases and Hepatology, Medical University of Białystok, Poland
  3. Department of Haematology and Bone Marrow Transplantation, Poznań University of Medical Sciences, Poland
  4. Provincial Hospital of Infectious Diseases and Medical University in Warsaw, Poland
  5. Department of Haematology, Institute of Haematology and Transfusion Medicine in Warsaw, Poland
  6. Department of Clinical Transplantology, Medical University of Lublin, Poland
  7. Department and Clinical Unit of Infectious Diseases and Hepatology, Medical University of Silesia in Katowice, Poland
  8. Department of Paediatrics, Haematology and Oncology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Poland
Clin Exp HEPATOL 2019; 5, 3:195–202
DOI: https://doi.org/10.5114/ceh.2019.87631
Online publish date: 2019/09/05
View full text Get citation
 
PlumX metrics:
Hepatitis B virus (HBV) is one of the main causes of chronic liver diseases and hepatocellular carcinoma. After infection the majority of HBV-infected patients achieve immune control leading to HBV-DNA stabilization at a low level. The risk of HBV reactivation rises significantly when HBV-infected patients receive immunosuppressive treatments. Presented recommendations provide guidelines for management of patients scheduled or undergoing therapies, which through their immunomodulatory activity contribute to the impairment of antiviral immunity, including chemotherapy, immunosuppressive treatment or biological therapy.
keywords:

HBV, prevention, reactivation
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.